Howe & Rusling’s Revolution Medicines RVMD Stock Holding History

Howe & Rusling’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-30	Closed	-$1K	–	1177
2022 Q2	$1K	Buy	+30	New	+$584	﹤0.01%	991

Other funds holding RVMD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Howe & Rusling's RVMD Position: Q3 2022 in Review

Howe & Rusling sold out of Revolution Medicines (RVMD) in Q3 2022, closing a stake of 30 shares — an estimated $1K sold.

Howe & Rusling first reported a position in RVMD in Q2 2022 and held it in 1 quarter. The position peaked at $1K in Q2 2022. 142 funds tracked by Wall St. Rank hold RVMD as of Q3 2022.

Howe & Rusling reported no remaining Revolution Medicines position as of Q3 2022 after selling out during the quarter.
Howe & Rusling sold 30 Revolution Medicines shares in Q3 2022, an estimated $1K.
Howe & Rusling first reported a position in Revolution Medicines in Q2 2022 and held it in 1 quarter.
Howe & Rusling's Revolution Medicines position peaked at $1K in Q2 2022.
142 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.